Onyx Strengthens Commercial Team
News May 28, 2012
Onyx Scientific has bolstered its business development team with the appointment of an experienced new director.
Brian Jolly joins the contract manufacturing organization’s (CMO) UK team as Director of European Business Development and will be responsible for overseeing the company’s sales effort across Europe.
PhD qualified, Brian brings a wealth of experience to the company having spent over 25 years in a range of technical and commercial roles in specialty chemicals and the wider chemical industry.
Operating from MHRA and FDA licensed sites in UK and India, Onyx Scientific supports pharmaceutical and emerging biotech from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.
Denise Bowser, commercial director head at Onyx Scientific, said: “We are delighted to have Brian on board as he has a huge amount of commercial experience that will no doubt benefit the company’s continued growth.
“Although we have clients across the world, the European market remains a key one. It is therefore essential for us to have this level of expertise on the ground to service clients and potential customers.”
The CMO recently launched a new website (www.onyxipca.com) to reflect the company’s expanded service offering following its acquisition by Ipca Laboratories last year.
Its team in Sunderland, UK, has dovetailed its chemistry services with the scale-up and manufacturing services offered by Ipca in India.
New appointment Brian said: “The thing that attracted me to Onyx Scientific was the company’s ambition for growth. It is a dynamic business with a fantastic reputation for expertise and competence for reliably delivering on its commitments to customers.
“It’s a fantastic new challenge for me and I am convinced this business has a solid foundation on which it can now grow and be recognized as a key player in the global contract manufacturing marketplace.”
Working as a preferred partner of many of the world’s top pharma firms, its UK-based labs deal with complex chemistry and deliver early stage programs involving custom synthesis, lead optimization, process development, solid-state chemistry and GMP API synthesis. It is then able to scale-up, internally tech transfer and provide increased efficiency for clients from its commercial sites in India.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018